Clonal Spread of Levofloxacin-Resistant Streptococcus pneumoniae Invasive Isolates in Madrid, Spain, 2007 to 2009

Rodríguez-Avial, Iciar; Ramos, Belén; Ríos, Esther; Cercenado, Emilia; Ordobás, María; Sanz, Juan Carlos

doi:10.1128/aac.01380-10

Cited by 25 publications

(14 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All serotype 8 isolates were associated with genotype CC63, suggesting a capsular switching event. This clone expressing serotype 8 was first detected in the 2006 study (18), and it was disseminated in the Madrid area, mainly among HIV-positive patients, with one isolate showing FQ resistance and a ParC S79F amino acid substitution (26,41). In the present series, eight CC63-serotype 8 isolates were also isolated from patients at hospitals in Madrid, a fact that could explain the frequency of this serotype among Cip r pneumococci in 2012.…”

Section: Discussionmentioning

confidence: 48%

“…These cases tend to involve elderly patients with chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), in which higher rates of FQ resistance have been detected (24). Although the development of FQ resistance has been associated with FQ consumption (14,22,25), the dissemination of pneumococcal FQ-resistant clones has rarely been observed so far (26). However, previous epidemiological studies (17,18) have re-vealed a low genetic diversity of pneumococcal clones among FQresistant pneumococci in Spain.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Fluoroquinolone-Resistant Pneumococci: Dynamics of Serotypes and Clones in Spain in 2012 Compared with Those from 2002 and 2006

Domenech

Tirado-Vélez

Fenoll

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 48%

mentioning

confidence: 99%

Fluoroquinolone-Resistant Pneumococci: Dynamics of Serotypes and Clones in Spain in 2012 Compared with Those from 2002 and 2006

Domenech

Tirado-Vélez

Fenoll

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

“…Other species, such as Haemophilus spp. and ␤-hemolytic streptococci, have been less prone to becoming fluoroquinolone nonsusceptible but are emerging at high rates in some countries (25)(26)(27)(28)(29)(30)(31). Hampering the advancement of fluoroquinolones to include other more potent agents has been difficult, due to the safety profile observed for this class.…”

Section: Discussionmentioning

confidence: 99%

In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens

Biedenbach¹,

Huband

Hackel³

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Following the introduction of nalidixic acid into clinical practice in the 1960s, fluoroquinolones have undergone profound structural modifications, leading to the development of numerous molecules in this class (1-3). Modifications to the quinolone structure, particularly the addition of fluorine(s) at key positions, have provided compounds with increased potency, broader spectrum of activity, and acceptable safety profiles. However, safety has been problematic in fluoroquinolone development (4-6). Several potent compounds have either been determined to be unsuitable for human use due to unacceptable toxicities, have required black box warnings on their labels, have been restricted to topical applications, or have resulted in removal from the market (7-9). Resistance development to fluoroquinolones is also becoming a significant concern among several Gram-positive and Gramnegative pathogens, including Staphylococcus aureus, Escherichia coli, and Neisseria gonorrhoeae.AZD0914 is a new orally administered spiropyrimidinetrione bacterial DNA gyrase inhibitor that demonstrates a novel mode of inhibition distinct from that of fluoroquinolones (10, 11). AZD0914 is a selective and potent inhibitor of the supercoiling and decatenation activity of DNA gyrase and topoisomerase IV, with the ability to overcome fluoroquinolone resistance by the inhibition of DNA biosynthesis through the accumulation of double-stranded cleaved DNA bound to the tetramer topoisomerase II.AZD0914 has a primary spectrum of activity that includes clinically relevant Gram-positive and fastidious Gram-negative bacterial species, including N. gonorrhoeae (12)(13)(14)(15). Published in vitro data on Chlamydia trachomatis and Chlamydia pneumoniae have shown that AZD0914 also has activity against these species (16). Its activity is maintained against strains with common fluoroquinolone resistance mutations in gyrase and topoisomerase IV within the quinolone resistance-determining region (QRDR) (12). Resistance to other key antimicrobial classes, such as ␤-lactams, macrolides, and glycopeptides, also do not diminish the activity of AZD0914. Currently, AZD0914 is being investigated in phase 2 trials for the treatment of uncomplicated N. gonorrhoeae infections (14,15).In this study, the in vitro activity of AZD0914 against key bacterial groups isolated from intra-abdominal, urinary tract, skin and soft tissue, and respiratory tract infections collected in a 2013 global surveillance survey was analyzed and compared to that of levofloxacin, moxifloxacin, and other nonfluoroquinolone compounds.(This study was presented, in part, at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy in 2014 [12].) MATERIALS AND METHODSClinical isolates (n ϭ 21,152) from hospitalized patients were collected at 169 medical centers in 39 countries distributed across North America, Latin America, Europe, Asia-Pacific, and Middle East/Africa during 2013. Isolates were obtained from specimens collected from patients with documented intra-abdominal infections...

show abstract

“…Reports in some countries have suggested that fluoroquinolone resistance in S. pneumoniae may be increasing [17]. Among …”

Section: Streptococcus Pneumoniaementioning

confidence: 99%

Advances in antibiotic therapy for community-acquired pneumonia

Viasus

García-Vidal²,

Carratalà³

2013

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

show abstract

Clonal Spread of Levofloxacin-Resistant Streptococcus pneumoniae Invasive Isolates in Madrid, Spain, 2007 to 2009

Cited by 25 publications

References 20 publications

Fluoroquinolone-Resistant Pneumococci: Dynamics of Serotypes and Clones in Spain in 2012 Compared with Those from 2002 and 2006

Fluoroquinolone-Resistant Pneumococci: Dynamics of Serotypes and Clones in Spain in 2012 Compared with Those from 2002 and 2006

In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens

Advances in antibiotic therapy for community-acquired pneumonia

Contact Info

Product

Resources

About